JP7500083B2 - 細胞含有医薬組成物 - Google Patents

細胞含有医薬組成物 Download PDF

Info

Publication number
JP7500083B2
JP7500083B2 JP2021541368A JP2021541368A JP7500083B2 JP 7500083 B2 JP7500083 B2 JP 7500083B2 JP 2021541368 A JP2021541368 A JP 2021541368A JP 2021541368 A JP2021541368 A JP 2021541368A JP 7500083 B2 JP7500083 B2 JP 7500083B2
Authority
JP
Japan
Prior art keywords
macrophages
cells
cell population
cell
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021541368A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021033247A1 (cg-RX-API-DMAC7.html
JPWO2021033247A5 (cg-RX-API-DMAC7.html
Inventor
孝之 浅原
エー. サルベコフ、アマンケルディ
誠 関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELLAXIA INC.
Original Assignee
CELLAXIA INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELLAXIA INC. filed Critical CELLAXIA INC.
Publication of JPWO2021033247A1 publication Critical patent/JPWO2021033247A1/ja
Publication of JPWO2021033247A5 publication Critical patent/JPWO2021033247A5/ja
Application granted granted Critical
Publication of JP7500083B2 publication Critical patent/JP7500083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021541368A 2019-08-19 2019-08-19 細胞含有医薬組成物 Active JP7500083B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/032322 WO2021033247A1 (ja) 2019-08-19 2019-08-19 細胞含有医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2021033247A1 JPWO2021033247A1 (cg-RX-API-DMAC7.html) 2021-02-25
JPWO2021033247A5 JPWO2021033247A5 (cg-RX-API-DMAC7.html) 2022-08-26
JP7500083B2 true JP7500083B2 (ja) 2024-06-17

Family

ID=74659865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541368A Active JP7500083B2 (ja) 2019-08-19 2019-08-19 細胞含有医薬組成物

Country Status (4)

Country Link
US (1) US12460182B2 (cg-RX-API-DMAC7.html)
JP (1) JP7500083B2 (cg-RX-API-DMAC7.html)
KR (1) KR102791419B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021033247A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372782B2 (ja) 2012-09-28 2018-08-15 公益財団法人神戸医療産業都市推進機構 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027474A1 (ja) 2012-08-17 2014-02-20 株式会社Clio 心筋梗塞の修復再生を誘導する多能性幹細胞
AU2015297347B2 (en) 2014-08-01 2021-05-27 PuREC Co., Ltd Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
US20160287638A1 (en) 2015-04-02 2016-10-06 Stemedica Cell Technologies, Inc. Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease
EP3297615A1 (en) * 2015-05-20 2018-03-28 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for modulation polarization and activation of macrophages
EP3299453B1 (en) * 2016-09-23 2019-05-08 Xcell Medical Solutions, S.L. Cell therapy with polarized macrophages for tissue regeneration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372782B2 (ja) 2012-09-28 2018-08-15 公益財団法人神戸医療産業都市推進機構 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENG Z. et al.,Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis.,Cellular Immunology,2017年,Vol.311,p.46-53
MASUDA H. et al.,J. Am. Heart Assoc.,2014年,Vol.3,e000743

Also Published As

Publication number Publication date
KR20220003564A (ko) 2022-01-10
WO2021033247A1 (ja) 2021-02-25
JPWO2021033247A1 (cg-RX-API-DMAC7.html) 2021-02-25
KR102791419B1 (ko) 2025-04-08
US20220218744A1 (en) 2022-07-14
US12460182B2 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
Dazzi et al. The role of mesenchymal stem cells in haemopoiesis
US10722541B2 (en) Methods for treating radiation or chemical injury
Schatteman et al. Biology of bone marrow-derived endothelial cell precursors
US8747905B2 (en) Therapeutic use of CD31 expressing cells
Kim et al. Cultured human bone marrow–derived CD31+ cells are effective for cardiac and vascular repair through enhanced angiogenic, adhesion, and anti-inflammatory effects
JP7599953B2 (ja) 造血幹細胞を生成するための方法
JP2002500879A (ja) 幹細胞の精製ポピュレーション
US10874698B2 (en) Therapy using cardiac stem cells and mesenchymal stem cells
JP2023504573A (ja) 造血幹細胞を生成するための方法
JP2024515690A (ja) 疾患の治療のための間葉系間質細胞からの細胞外小胞
US6821513B1 (en) Method for enhancing hematopoiesis
JPWO2020158924A1 (ja) 母児間免疫寛容を誘導する方法
Rivera-Torruco et al. Exploring extramedullary hematopoiesis: unraveling the hematopoietic microenvironments
CN114901806B (zh) 细胞群以及其取得方法
Tamura et al. In vivo differentiation of stem cells in the aorta-gonad-mesonephros region of mouse embryo and adult bone marrow
Madariaga et al. Kidney‐Induced Cardiac Allograft Tolerance in Miniature Swine is Dependent on MHC‐Matching of Donor Cardiac and Renal Parenchyma
KR20230154177A (ko) 림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물
JP2002523039A (ja) 非胎児血管芽細胞を含む細胞集団、およびその生産方法
KR102791419B1 (ko) 세포 함유 의약 조성물
WO2007047963A2 (en) Use of bone-marrow derived stem cells to treat ischemia
WO2009046058A1 (en) A method to amplify cardiac stem cells in vitro and in vivo
US9901639B2 (en) Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
Jozkowicz et al. Vasculogenesis—a new strategy for induction of peripheral neovascularization
Efimenko et al. Viability and angiogenic activity of mesenchymal stromal cells from adipose tissue and bone marrow under hypoxia and inflammation in vitro
Gupte Pluripotent Hematopoietic Stem Cells Augment α-Adrenergic Receptor-Mediated 1 Contraction of Pulmonary Artery and Contribute to the Pathogenesis of Pulmonary 2 Hypertension 3

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240529

R150 Certificate of patent or registration of utility model

Ref document number: 7500083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150